These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 21383657

  • 1. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation.
    van Gelder T, Silva HT, de Fijter H, Budde K, Kuypers D, Mamelok RD, Armstrong VW, Oellerich M.
    Ther Drug Monit; 2011 Apr; 33(2):155-64. PubMed ID: 21383657
    [Abstract] [Full Text] [Related]

  • 2. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
    van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hené RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ.
    Transplantation; 1999 Jul 27; 68(2):261-6. PubMed ID: 10440399
    [Abstract] [Full Text] [Related]

  • 3. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb 27; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 4. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
    Kiberd BA, Lawen J, Daley C.
    Ther Drug Monit; 2012 Dec 27; 34(6):736-8. PubMed ID: 23007746
    [Abstract] [Full Text] [Related]

  • 5. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT, Rousseau A, Bosmans JL, Senessael JJ, Cumps J, Marquet P, Wallemacq P, Verbeeck RK.
    Clin Pharmacokinet; 2009 Dec 27; 48(11):745-58. PubMed ID: 19817503
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
    van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K, Kuypers D, Le Meur Y, van der Werf M, Mamelok R, van Gelder T.
    Clin Pharmacol Ther; 2009 Sep 27; 86(3):319-27. PubMed ID: 19494809
    [Abstract] [Full Text] [Related]

  • 9. Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium?
    Ding C, Xue W, Tian P, Ding X, Pan X, Xiang H, Tian X, Li Y, Zheng J.
    Int J Clin Pract Suppl; 2014 Apr 27; (181):10-6. PubMed ID: 24673714
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
    Grinyó JM, Ekberg H, Mamelok RD, Oppenheimer F, Sánchez-Plumed J, Gentil MA, Hernandez D, Kuypers DR, Brunet M.
    Nephrol Dial Transplant; 2009 Jul 27; 24(7):2269-76. PubMed ID: 19357111
    [Abstract] [Full Text] [Related]

  • 12. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun 27; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.
    van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, Le Meur Y, Oellerich M, Holt DW, Tönshoff B, Keown P, Campbell S, Mamelok RD.
    Transplantation; 2008 Oct 27; 86(8):1043-51. PubMed ID: 18946341
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
    van Agteren M, Armstrong VW, van Schaik RH, de Fijter H, Hartmann A, Zeier M, Budde K, Kuypers D, Pisarski P, Le Meur Y, van der Werf M, Mamelok RD, Oellerich M, van Gelder T.
    Ther Drug Monit; 2008 Aug 27; 30(4):439-44. PubMed ID: 18641546
    [Abstract] [Full Text] [Related]

  • 20. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    Clin Pharmacokinet; 2004 Aug 27; 43(11):741-62. PubMed ID: 15301578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.